Cardiovascular disease (CVD) comprises the largest cause of morbidity and mortality in people with type 2 diabetes (T2D).1
There is a paucity of data on the prevalence of CVD among people with T2D.
Recent findings from cardiovascular (CV) outcomes trials showed a CV benefit with some GLP-1 receptor agonists and SGLT-2 inhibitors and are changing treatment recommendations.2
Understanding the impact of this paradigm shift requires data on the prevalence of CVD in people with T2D.
How was this study conducted?
CAPTURE was a multinational, cross-sectional, non-interventional study of adults aged ≥18 years with T2D attending a single routine healthcare visit in primary or specialist care between December 2018 and September 2019.
The primary endpoint was overall prevalence estimate of CVD across all 13 countries, weighted to account for the size of the diabetes population of each country.
Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020 Feb;63(2):221-8.
Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018 Jun 8;17(1):83.
This is a highlights summary of an oral session given at the EASD 2020 Virtual Meeting and presented by:
Ofri Mosenzon, MD, PhD
Ichan School of Medicine at Mount Sinai, New York, NY, USA
The presenting authors of the original session had no part in the creation of this conference highlights summary.
The content is produced by Infomedica. The summary text was drafted by Patrick Moore, PhD, and reviewed by Marco Gallo, MD, an independent external expert, and approved by Florian Toti, MD, the scientific editor of the program.